Screening programme for phenylketonuria in the Gaza Strip: evaluation and recommendations

Abdel Nasser K Abu Shahla1, Yehia Abed, Nabegha K Abu Shahla

  • 1Biology Department, Al-Azhar University, Gaza, Palestine. drabushahla@hotmail.com

Insights

Phenylketonuria (PKU) screening in Gaza has low coverage, with many newborns untested. Improvements are needed for early detection and management of this inherited metabolic disorder.

Area of Science:

  • Medical Screening Programs
  • Newborn Health
  • Metabolic Disorders

Background:

  • Phenylketonuria (PKU) is an inherited metabolic disorder causing progressive mental retardation.
  • Early newborn screening and medical follow-up are crucial for preventing PKU complications.
  • The Palestinian national screening program for PKU in the Gaza Strip requires evaluation.

Purpose of the Study:

  • To evaluate the Palestinian national newborn screening program for Phenylketonuria (PKU) in the Gaza Strip.
  • To assess the prevalence, coverage, and effectiveness of PKU screening and management in the region.

Main Methods:

  • Retrospective analysis of PKU screening data from Palestinian Ministry of Health (MOH) records for the year 2000.
  • Interviews with PKU patients and their families in the Gaza Strip.
  • Data collection focused on screening coverage, testing timing, consanguinity rates, dietary management, and patient monitoring.

Main Results:

  • Overall PKU prevalence in Gaza was 6.35/100,000, with a peak of 28.3/100,000 in rural areas.
  • Screening coverage was limited to 35.3% of newborns at government clinics; UNRWA clinics had no testing.
  • Delayed testing (after 17 days) was common, and only 43.1% of patients received specialized low-phenylalanine milk; monitoring was inconsistent.

Conclusions:

  • The PKU screening program in Gaza requires significant improvement in coverage and methodology.
  • Recommendations include expanding screening to all newborns, reviewing testing protocols, and enhancing patient management.
  • Addressing challenges in screening and follow-up is essential for preventing severe complications of Phenylketonuria.

Related Concept Videos